drugset / Trial / NCT02264171

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

NCT02264171

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the effect of CYP3A4 inhibition by ketoconazole on the single oral dose pharmacokinetics of tamsulosin and to investigate the effect on safety and tolerability

Timeline

Start
2008-04
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule
Subject Tamsulosin Other / unclassified Oral

Indications

No indication recorded.